Facebook Twitter LinkedIn Google Plus RSS

Cancer Genetics Inc. closes $15M public offering

By ,

Cancer Genetics Inc., a Rutherford maker of cancer diagnostics tests, has announced the closing of its previously announced public offering of 1.5 million shares of its common stock at $10 per share.

The gross proceeds to Cancer Genetics from the offering, first announced last week, were $15 million before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics, according to the announcement. The company has also granted the representative of the underwriters a 45-day option to purchase up to 225,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any.

Aegis Capital Corp. acted as sole book-running manager for the offering, while Feltl and Company, Inc. acted as co-lead manager for the offering, the company said in its statement.

Digital content editor Joe Ross is @joeross on Twitter.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!